In our prospective cohort of CIS and early RRMS patients we found low spontaneous MxA mRNA levels in the first months after diagnosis to be associated with the occurrence of a larger number of new T2 lesions during a median follow-up period of 11 years. The gene discussed is MX1; the disease is in situ carcinoma.